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Abstract
Introduction: In Brazil, more than 487,450 individuals are currently undergoing antiretroviral treatment. In order to monitor
the transmission of drug-resistant strains and HIV subtype distribution in the country, this work aimed to estimate its preva-
lence and to characterize the nationwide pretreatment drug resistance in individuals recently diagnosed with HIV between
2013 and 2015.
Methods: The HIV threshold survey methodology (HIV-THS, WHO) targeting antiretroviral-naive individuals with recent HIV
diagnosis was utilized, and subjects were selected from 51 highly populated cities in all five Brazilian macroregions. The HIV
pol genotypic test was performed by genomic sequencing.
Results: We analysed samples from 1568 antiretroviral-naive individuals recently diagnosed with HIV, and the overall trans-
mitted drug resistance (TDR) prevalence was 9.5% (150 sequences). The regional prevalence of resistance according to Brazil-
ian geographical regions was 9.4% in the northeast, 11.2% in the southeast, 6.8% in the central region, 10.2% in the north and
8.8% in the south. The inhibitor-specific TDR prevalence was 3.6% for nucleoside reverse transcriptase inhibitors (NRTIs),
5.8% for non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 1.6% for protease inhibitors (PIs); 1.0% of individuals
presented resistance to more than one class of inhibitors. Overall, subtype B was more prevalent in every region except for
the southern, where subtype C prevails.
Conclusions: To the best of our knowledge, this is the first TDR study conducted in Brazil with nationwide representative
sampling. The TDR prevalence revealed a moderate rate in the five Brazilian geographical regions, although some cities pre-
sented higher TDR prevalence rates, reaching 14% in S~ao Paulo, for example. These results further illustrate the importance
of surveillance studies for designing future strategies in primary antiretroviral therapy, aiming to mitigate TDR, as well as for
predicting future trends in other regions of the globe where mass antiretroviral (ARV) treatment was implemented.
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1 | INTRODUCTION
The Brazilian Ministry of Health implemented, in 1996, a
pioneering programme for the care and support of people liv-
ing with HIV/AIDS, which encompasses free universal access
to antiretroviral drugs for HIV-infected individuals. Besides
the undoubted benefits of such policy, antiretroviral resistance
remains one of the major obstacles to sustain HIV suppression
during antiretroviral therapy (ART) [1,2]. Transmitted drug
resistance (TDR), has been associated with first-line antiretro-
viral virological failure in Brazil [3], and may as well compro-
mise other therapeutic interventions, such as pre-exposure
prophylaxis (PrEP), prevention of mother-to-child transmission
(PMTCT) and post-exposed prophylaxis (PEP) [2].
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It is important to highlight that the treatment practices
adopted by different countries can greatly influence TDR
rates and substantial differences can be reported worldwide.
In high-income countries, the number of newly infected
patients that carry at least one major drug resistance muta-
tion can vary from 7% to 17% [2,4,5]. A recent study analysed
samples from 26 European countries and reported an overall
prevalence of TDR of 8.3%. Countrywide studies identified
TDR rates of 11.2% in the United States [6], 5.6% in Sweden
[7], 14.7% in Romania [8] and 9.9% in Spain [9]. In middle-
and low-income countries, the prevalence of TDR is around
7.0%, estimated at 6.3% in Latin America [4], 5.7% in India
[10] and less than 5.0% in major African countries, including
Angola, Botswana, South Africa, Uganda, Zimbabwe and Chad
[11].
Brazil has recently adopted the Test and Treat policy and
has an increasing number of patients in antiretroviral treat-
ment at specialized AIDS clinics. In December 2015, more
than 455,000 individuals were receiving antiretroviral treat-
ment in Brazil, accounting for almost 68% of the HIV-infected
individuals who are followed by the Brazilian Public Health
System.
In order to monitor the transmission of drug-resistant
strains, as well as the HIV subtype distribution in Brazil, the
Brazilian Ministry of Health has established the National Net-
work for Drug Resistance Surveillance (HIV-BresNet). The first
survey, conducted on 2001, showed an overall rate of trans-
mitted resistance of 6.6%, with an even distribution of pro-
tease and reverse transcriptase inhibitors resistance-related
mutations [12]. In the second survey, carried out between
2007 and 2008, TDR mutations were found in 8.1% of the
studied population, and an intermediate level of transmitted
resistance (between 5% and 15%) was found in major Brazil-
ian cities, such as Belem, Brasilia, S~ao Paulo and Rio de
Janeiro [13].
Brazil is a continental country, and its different geographical
regions have unique demographics as well as AIDS incidence.
Therefore, determining a homogeneous picture of the Brazil-
ian HIV/AIDS epidemic may be challenging. In order to pro-
vide important data for the elaboration and revision of
policies regarding prevention, treatment and care of HIV, this
work aimed to estimate its prevalence and characterize the
nationwide pretreatment drug resistance in individuals
recently diagnosed with HIV, referred to as the first viral load
test.
2 | METHODS
2.1 | Sampling
A countrywide sampling was conducted in Brazil’s five major
geographical regions: north, northeast, central-west, southeast
and south. For this purpose, we have included 72 laboratories
from the Brazilian Network for HIV Viral Load testing in 51
cities throughout the country. All patients were recently diag-
nosed and samples were collected before ARV onset. Each
region had probability proportional to size (PPS) sampling
based on the information of the number of people who initi-
ated ART in the previous time period. The standard sample
size was 254, according to the WHO protocol for Surveillance
of HIV drug resistance in adults initiating ART [14]. Based on
it, at least 254 samples were collected per region and dis-
tributed for each state maintaining the ratio of samples tested
for viral load for the first time between 2013 and 2015. In
view of the HIV/AIDS epidemic in Brazil, which is highly con-
centrated in the southeast, the sample size was doubled to
508 in this region to prevent any sampling bias. The criteria
for inclusion were: (i) 18 years old or older; (ii) first viral load
at the Brazilian Ministry of Health National Network Labora-
tories; and (iii) ART-naive individuals according to the Brazilian
National System of Drugs Logistic Control (SICLOM). The eth-
ical issues of this study were reviewed by UFRJ-IRB under #
30459614.9.0000.5257. This study was approved without the
need for signed consent from volunteers, allowing the use of
information available on the application form used for viral
load exams only.
2.2 | Genotypic analyses
Nineteen laboratories were responsible for running the HIV
genotypic test using the TRUGENE HIV-1 Genotyping Kit
and the OpenGene DNA Sequencing System (Siemens
Healthcare Diagnostics, Tarrytown, NY, USA) and the quality
of the test was assured using an external quality proficiency
panel distributed by the Brazilian Ministry of Health, as previ-
ously described [15]. Resistance mutations were assigned by
the Calibrated Population Resistance (CPR) algorithm [16],
which is based on the WHO drug resistance mutation list for
surveillance of transmitted HIV-1 drug resistance [17]. Addi-
tional analyses were conducted in order to verify pretreat-
ment drug resistance, following WHO guidelines [14], using
the HIVdb Program [18]. HIV-1 subtype assignments were
defined according to the REGA HIV-1 Automated Subtyping
Tool [19,20] and the HIVdb Program [18].
2.3 | Statistical analysis
Results of qualitative variables were represented as total
counts and frequency and a Pearson’s Chi-squared test was
applied for comparisons between genders, geographical
regions and HIV subtypes. Results of quantitative variables
(age and viral load) were represented as mean and standard
deviation. Adherence to normal distribution was assessed using
the Shapiro-Wilk test. A Kruskal-Wallis rank sum test was
applied for overall comparisons of quantitative data between
regions and a Dunn’s post hoc test was applied for pairwise
comparisons with the Bonferroni adjustment. Age and viral
load comparisons between genders were performed using a
Mann-Whitney test. All analyses were performed using R for
Windows 3.2.0 (R Development Core Team, Vienna, Austria).
3 | RESULTS
3.1 | Sampling
In this study, samples were collected from October 2013 to
January 2015, at the 72 viral load laboratories members of
the Brazilian Ministry of Health National Network Laborato-
ries. From this sampling, 1568 had the first 1000 nucleotides
of pol region appropriately sequenced (GenBank accession
numbers KX887502 to KX889067), attending the CPR algo-
rithm. With the exception of the southeast region, which had
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500 sequenced samples instead of the estimated number
(508 samples), the sampling size inferred according to the
PPS methodology was reached (see Supporting Information).
Information concerning demographic parameters such as
age and gender, as well as viral loads, was available for 1319
individuals. In general, the number of male samples (N = 919,
70%) was higher than female (N = 400, 30%), with the former
composed of significantly younger individuals when compared
to the latter (p < 0.0001). The viral load was also significantly
higher in males (4.79  0.90 log10 copies/ml) than females
(4.61  0.90 log10 copies/ml) (p < 0.001) (Table 1). Compar-
isons of viral loads according to geographical region have also
shown a statistically significant variation (p < 0.001; Kruskal-
Wallis test). Results of post hoc comparisons have showed that
viral loads were significantly lower in the southeast (4.602 
0.876) as compared to the northeast (4.857  0.927) and
southern (4.835  0.924) regions (p < 0.01).
3.2 | TDR analyses
TDR analyses based on the CPR algorithm were conducted
for each geographical region separately (see Supporting Infor-
mation for details). The presence of any TDR in the analysed
sequences from each Brazilian region varied from 6.8%
(n = 18) in the central-west region to 11.2% (n = 56) in the
southeast region. The prevalence of resistance to each drug
class was similar in the different Brazilian regions (Table 2).
When considering each antiretroviral class a higher preva-
lence of TDR was identified for non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), ranging from 4.5% (n = 12) in
the northeast and central-west to 7.0% (n = 19) in the south
(Table 2, Figure 1). Prevalence of TDR to NNRTIs was signifi-
cantly higher than to nucleoside reverse transcriptase inhibi-
tors (NRTIs) in an analysis considering subjects from all
regions and also among subjects from the southern region
(p < 0.01, both). As expected, prevalence of resistance to
reverse transcriptase inhibitors (NRTI/NNRTI) was signifi-
cantly higher than to protease inhibitors (PI; p < 0.01) in all
Brazilian regions (Table 2). The north was the only region
which showed one sequence with TDR to three antiretroviral
classes (n = 1, 0.4%) (Figure 1).
Concerning the NRTI mutations, M41L was the most preva-
lent in the north (n = 7, 2.6%) and south (n = 2, 0.7%),
whereas T215Y/D/S/E/I/V was highly prevalent in the north-
east (n = 6, 2.3%), central-west (n = 5, 1.9%) and southeast
(n = 7, 1.4%). Additional NNRTI mutations were identified at
K65, D67, T69, K70, V75, M184 and L210 (Figure 2a).
Regarding NNRTI-related mutations, K103N/S was the
most prevalent variation in all regions: 4.2% in north (n = 11),
3.8% in the northeast (n = 10), 3.4% in the central-west
(n = 9), 5.0% in the southeast (n = 25) and 5.5% in the south
(n = 15). The NNRTI mutations were also identified at the
positions L100, K101, V106, V179, Y181, Y188, G190 and
P225 (Figure 2b).
Regarding the PI mutations, M46I/L was the most prevalent
in the north (n = 2, 0.8%), northeast (n = 4, 1.5%), central-
west (n = 1, 0.4%), southeast (n = 4, 0.8%) and south (n = 2,
0.7%). V82A/L mutations were highly prevalent in the north-
east (n = 4, 1.5%) and north (n = 4, 1.5%). PI mutations were
also detected at L24, D30, V32, M46, I47, I50, F53, I54, V84,
N88 and L90 (Figure 2c).
3.3 | HIV-1 subtyping assignment
The HIV subtype characterization was evaluated for the 1568
analysed pol sequences using the REGA HIV-1 subtyping tool
[19,20] and HIVdb Program [18]. With the exception of the
south, the subtype B (n = 1045, 66.8%) remains the most
prevalent in Brazil, followed by subtypes C (n = 223, 14.2%)
and F (n = 156, 10%). We also found CRFs composed of sub-
types B, C and F sequences spread throughout the regions.
The CRF31 (B/C) was present in the southern region account-
ing for 8.1% of all sequences analysed for this region, and the
CRF31 variant was also found in the southeast (0.2%) and
central-west (0.4%). In addition, CRF 12 and 29, composed of
B and F sequences, were found in the central-west (0.4%
Table 1. Distribution of age, gender and viral loads according to regiona
Total North Northeast South Southeast Central-West
Age (years)b 35  12 34  11 35  11 37  12 35  12 36  12
Male 34  11.5 34  11 34  12 35  12 34  11 35  11
Female 37  12.5 34  12 37  10 38  13 38  13 37  13
Genderc
Male 919 (70) 168 (68) 119 (70) 153 (64) 336 (72) 143 (72)
Female 400 (30) 78 (32) 52 (30) 86 (36) 129 (28) 55 (28)
Viral load
Maled 4.793  0.901 4.8  0.9 4.899  0.889 4.942  0.877 4.647  0.879 4.872  0.931
Female 4.614  0.896 4.684  0.846 4.762  1.012 4.652  0.977 4.483  0.862 4.634  0.768
Totale 4.739  0.903 4.763  0.898 4.857  0.927 4.835  0.924 4.602  0.876 4.805  0.892
aData is presented as N (%) for gender and mean  SD (standard deviation) for age and viral loads.
bp < 0.0001 for comparisons according to regions (Kruskal-Wallis test).
cTotal counts do not add up to the total number of subjects in this study (1319 against 1568 individuals) due to missing information.
dp < 0.001 for comparisons of viral loads according to gender in the total sample (All) and p < 0.05 for the same comparison in the south and
southeast regions (Mann-Whitney test).
ep < 0.001 for comparisons of viral loads according to regions (Kruskal-Wallis test) and p < 0.01 for comparisons between southeast and north-
east and between southeast and south regions (Dunn’s post hoc test).
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CRF12 and 0.8% CRF29), southeast (0.6% CRF12 and 0.4%
CRF29), south (0.4% CRF12 and 0.4% CRF29) and northeast
regions, where only CRF12 was found (0.4%). CRF01_AE and
CRF02_AG were identified in the central-west and northeast
regions respectively (Figure 3). Unique recombinant forms
(URFs) composed by complex subtype pattern between B, C,
F and K sequences were found all over the country, account-
ing for 6.3% of all isolates analysed. No differences between
prevalence of TDR among different subtypes have been
observed.
Subtype C was the most prevalent in the south of Brazil
(n = 147, 53.8%), followed by subtype B (n = 84, 30.8%),
CRF31 (n = 22, 8.1%) and subtype F (n = 9, 3.3%) (Figure 3).
4 | DISCUSSION
This is the first survey including samples from all Brazilian
states, therefore truly representative of all five Brazilian geo-
graphical macroregions, analysing 1568 samples of recently
diagnosed individuals collected between 2013 and 2015. It is
interesting to noticed that the majority of our subject
included, young male, reflects the new HIV wave of epidemic
affecting young MSM (http://unaids.org.br/estatisticas/).
Our data enabled us to demonstrate the prevalence of TDR,
varying from 6.8% (n = 18) in the central-west to 11.2%
(n = 56) in the southeast. Based on the WHO HIVDR classifi-
cation, all Brazilian macroregions showed intermediate level of
resistance (5% to 15%). These prevalences are similar to the
ones previously described in Brazil, as seen in Figure 1. How-
ever, higher prevalence has occasionally been described in the
cities of Salvador, located in the northeast region of Brazil
(18.9% and 17.0%) [21,22] and Santos [23], in the southeast
region of Brazil (29.2% and 17.0%) [22,24]. Our data is also
consistent with other South American countries where mass
treatments are provided. In a similar study done in Argentina,
researchers found 14% of TDR and 11% of NNRTI DRM [25].
Although this study has not been designed to measure the
transmitted resistance in each Brazilian state/city separately,
we were able to observe that the state of S~ao Paulo has pre-
sented higher levels of SDRM (surveillance drug-resistance
mutation) than the other studied regions (data not shown),
reaching 14% (28 resistant samples from 198 analysed). S~ao
Paulo, the most populous state in Brazil, was the first to start
treatment with antiretrovirals in the 1990s; more than 40%
of patients receiving antiretroviral treatment in Brazil are in
this state, whereas the city of S~ao Paulo alone is responsible
for almost 25% of all antiretroviral treatment in Brazil. There-
fore, it is conceivable that long-term exposure to antiretrovi-
rals, which relates to sequential monotherapy and exposure to
unboosted PIs, could increase the odds for antiretroviral fail-
ure and consequent TDR.
We observed a high prevalence of K103N – the NNRTI
mutation – in recently diagnosed individuals in all regions of
Brazil, ranging from 3.4 to 5.5%, compatible to world trends
for this drug class [26]. There have been speculations that
NNRTI mutations can be more readily transmitted due to the
higher exposure to this drug class, as well as to its limited
effect on the replicative capacity of the virus, therefore per-
sisting for longer periods of time. This is a great concern in
Brazil, since the protocol for initial treatment advocates theT
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fixed dose combination of tenofovir/3TC/efavirenz (http://
www.aids.gov.br/pcdt) [27]. It is also interesting to note that,
as seen in Figure 2b, and in accordance to the frequent
antiretroviral exposure in Brazil, the efavirenz related NNRTI
pathway for resistance [25], which includes mutation at
codons 103 associated to codons 100, and 225, is more fre-
quently observed than the nevirapin pathway for resistance,
which includes mutation at codons 181 and 101, the latter
leading to cross-resistance to etravirine. Mutation at codon
103 was followed by NRTI mutations, with a high prevalence
of the so-called T215 revertants (215 D/I/V/S, Figure 2a),
which are products of the evolution of T215Y or T215F.
Although the revertants per se do not present any level of
phenotypic resistance [28], it is plausible that individuals har-
bouring these revertants may also harbour the T215Y or
T215F strains, which are associated with virological antiretro-
viral failure [29]. Of course, it is theoretically possible that the
revertants were transmitted rather than the original T215Y
or T215F strains, and the analysis of minority HIV populations
using next-generation sequencing techniques may be able to
answer this important and interesting question. Again, in this
study, the mutation at codon 184, generally the more preva-
lent secondary resistance mutation, has a very low prevalence
in this study, possibly related to the higher probability of this
mutation to revert to a wild-type over time [27], which may
be a note of caution among individuals presenting TDR muta-
tions. The presence of minority HIV populations presenting
M184V/I mutations among individuals already presenting TDR
may also be a subject for future studies using next-generation
sequencing techniques in TDR surveys.
It is important to note in Figure 2 panel C that prevalence
of PI related TDR is lower than previously documented in Bra-
zil [13,30], possible related to a trend of increased use of
boosted PIs over time which is also associated to a decreased
prevalence of secondary PI resistance mutations over time in
Brazil [30]. Nonetheless, it is also interesting to note that,
mutations at protease codons 30, 88, 46 and 82, which relate
to PIs such as nelfinavir, indinavir and ritonavir, which have not
been used in Brazil for very long, are still being transmitted.
This finding suggests that this TDR mutation has been occur-
ring, unnoticed, from patient to patient for a very long time.
In accordance to what has been previously shown in Brazil
[31], the subtype C is more prevalent in the southern region,
probably due to a founder effect, accounting for prevalence
over 50%. Subtype C was also present in all regions of Brazil,
in people who were recently diagnosed with HIV-1 infection,
showing its spreading capacity. Together with subtype C, we
found a substantial amount of CRF31 isolates in our sampling.
This CRF was more present in the southern region; however,
we encountered them throughout the central-west and south-
east regions as well. According to predictions using the Baye-
sian Markov chain Monte Carlo (MCMC) methods and the
reversible-jump MCMC method, HIV-1 subtype B emerged in
1971, subtype F emerged in 1981, BF recombinants emerged
in 1989, subtype C emerged in 1987 and BC recombinants
emerged in 1992 [32–34]. This study also predicted that the
basic reproductive number of secondary infections
(R0 = 5 year interval) is 2.4 for Brazilian subtype B strains, 2.3
for subtype F and 4.6 for subtype C, warning for the faster
expansion of this latter in the Brazilian epidemics [32]. It is also
worth mentioning, that one study analysing phenotypic resis-
tance in a limited number of samples from antiretroviral-naive
individuals in Brazil revealed that some subtype C strains pre-
sented phenotypic resistance no NRTIs and more frequently to
NNRTIs without significant genotypic mutations, which sug-
gests that the genotypic correlates of subtype C resistance
might not yet be clearly defined, posing an additional problem
related to the HIV-1 genetic diversity [35].
5 | CONCLUSIONS
In conclusion, we believe that the sampling technique used
herein provides, for the first time, results on TDR that are
truly representative of Brazil. The results presented reveal a
moderate rate of primary prevalence of TDR in the five Brazil-
ian macroregions. These results further illustrate the impor-
tance of surveillance studies in the development of future
strategies for mitigating TDR or initial treatment-related
strategies, as well as for helping to predict future trends in
other regions of the globe, where mass ARV treatment was
implemented.
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